Cannovation Clinical Research Partners Launches, Aiming to Revolutionize Cannabinoid-Based Therapeutics

Cannovation Clinical Research Partners, a new player in the pharmaceutical and biotech sector, has announced its inauguration in Atlanta, Georgia. The company was founded by Lisa Rich-Milan, a former pharmaceutical executive, and Michael Zaccaria, an experienced leader in the cannabis industry. Cannovation is set to focus on the development and commercialization of cannabinoid-based therapeutics.

The organization has dedicated itself to partnerships across pharmaceutical companies, biotechnology firms, universities, and other Centers of Excellence to push forward the research and development of cannabis-based drugs. Emphasizing a comprehensive approach, Cannovation will support all phases ranging from pre-clinical studies to commercialization in the U.S. market.

Both founders expressed their commitment to bridging the pharmaceutical and cannabis industries through innovation. Rich-Milan highlighted the goal of leveraging cannabinoids to transform medicine, while Zaccaria emphasized on advancing innovation and excellence within their collaborative sectors. Cannovation intends to utilize its broad network to assist clients from product development to launch, ensuring smooth navigations through regulatory frameworks.